Hormonal
Dual-agonists targeting GLP-1 and Glucagon receptors (e.g., Mazdutide, Survodutide) offer superior weight loss and metabolic improvements compared to GLP-1 monotherapies, though they carry a higher risk of gastrointestinal adverse events.
Mazdutide is a once-weekly injection targeting both GLP-1 and Glucagon receptors. In trials, a 9mg dose led to an 18.6% average body weight loss over 48 weeks, outperforming many single-hormone drugs. However, patients should be aware of a higher rate of gastrointestinal side effects compared to some GLP-1 monotherapies, which may lead to discontinuation.
Mazdutide... resulted in an 18.6% mean body weight decrease over 48 weeks... Patient discontinuation occurred in 12.5% (6 weeks) and 17.8% (16 weeks) of patients due to gastrointestinal, vascular, or cardiac adverse effects, respectively [Survodutide].
Why this rating
Based on Phase I/II trials showing significant weight loss but also high discontinuation due to side effects.
Source
Innovative Glucagon-based Therapies for Obesity
Kibret Enyew Belay et al. · Journal of the Endocrine Society · 2024
DOI 10.1210/jendso/bvae197
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →